z-logo
open-access-imgOpen Access
The Efficacy of Intramuscular Benzathine Penicillin for Preventing Recurrent Cellulitis: A Nationwide Population-Based Study
Author(s) -
Szu-Han Lin,
Yu-Lin Lee,
YenYu Chen,
YiChun Yeh,
Chun-Eng Liu
Publication year - 2017
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofx163.124
Subject(s) - medicine , cellulitis , penicillin , incidence (geometry) , population , medical prescription , surgery , pediatrics , antibiotics , microbiology and biotechnology , biology , optics , pharmacology , environmental health , physics
Background Recurrent cellulitis is a vexing clinical problem with huge financial burden on healthcare resources. Though intramuscular antibiotics had been suggested as a prevention strategy but the evidence is scarce. Methods We conducted a cohort study by using Taiwan’s National Health Insurance Research Database (NHIRD) between 2000 and 2008. Patients received intramuscular benzathine pencillin 2.4 MU every 4 weeks at least three prescriptions within half a year were enrolled and followed for 1 year since the first dose. The prevention efficacy was determined by comparing the incidence of recurrent cellulitis in the prophylactic period to non-prophylactic period in each enrolled subject by a Poisson regression model. The prophylactic period was defined as 4 weeks after the date of each dose of benzathine penicillin injection and non-prophylactic period was the time not covered by penicillin during the follow-up period. Results In total, 211 patients were enrolled, including 123(58.3%) men. An average of 7.9 doses of IM benzathine penicillin was given in the study period. The incidence rate of recurrent cellulitis in the prophylactic period was 0.31 episode/patient-year, significantly lower than that of 0.77 episodes/patient-year in the non-prophylactic period (P = 0.004). The common underlying diseases of enrolled patients included diabetes mellitus (73, 35.4%), tinea pedis (69, 33.5%), impaired venous drainage (20, 9.7%), joint replacement of lower extremity (13, 6.3%) and edema status including congestive heart failure (19, 9.2%), chronic renal failure (15, 7.3%), and cirrhosis (8, 3.9%). In multivariate analysis of Poisson regression model, penicillin prophylaxis was associated with lower recurrence (relative risk (RR), 0.30; 95% confidence interval (CI), 0.13–0.69, P = 0.005), in contrast, impaired venous drainage (RR 2.78; CI, 1.20–6.48, P = 0.018) and tinea pedis (RR 3.04; CI, 1.17–7.90, P = 0.022) were associated with higher risk of recurrence. Conclusion The study was the largest cohort that demonstrated intramuscular injection of 2.4 million units benzathine penicillin with 4-week interval significantly reduced the incidence of recurrent cellulitis. Disclosures All authors: No reported disclosures.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom